Engineering Approaches to Sickle Cell Disease
Springer International Publishing (Verlag)
978-3-032-12531-6 (ISBN)
- Noch nicht erschienen - erscheint am 11.02.2026
- Versandkostenfrei
- Auch auf Rechnung
- Artikel merken
Engineers have played an important and often underrecognized role in advances in the treatment and management of sickle cell disease and in recent curative breakthroughs. This comprehensive and cutting-edge edited volume brings together renowned experts to shed light on the development and application of engineering technologies to unravel the complexities of sickle cell disease in pursuit of improved health outcomes.
This volume is intended for researchers, engineers, scientists, clinicians, and students working in the fields of engineering, genetics, hematology and other related disciplines. Medical professionals seeking to stay abreast of the most recent technological breakthroughs in sickle cell disease treatments and cures will also find this book informative. Additionally, counselors, policy makers, healthcare administrators and anyone seeking to understand the impact of engineering solutions on advances in sickle cell disease, will be intrigued by the innovations, applications and future prospects shared in this important addition to sickle cell resources.
Gilda Barabino served as the second president of Olin College of Engineering where she currently holds an appointment as Professor of Biomedical and Chemical Engineering. Prior to Olin, she served as Dean of the Grove School of Engineering at the City College of New York (CCNY). She has also held academic and administrative appointments at Georgia Institute of Technology, Emory University, and Northeastern University.
A chemical engineering trailblazer in the fields of medicine and global health, she has pursued an equity ethic across her interdisciplinary career. Her seminal discoveries in sickle cell research and orthopedic tissue engineering have informed current technologies and formed the basis of novel therapies. At CCNY she established the Master s in Translational Medicine program, which addresses unmet clinical needs through the integration of engineering, medical innovation, and entrepreneurship.
She leads on a global stage and is a past president of the American Association for the Advancement of Science (AAAS), the world s largest interdisciplinary scientific society. She is also a past president of the Biomedical Engineering Society and the American Institute for Medical and Biological Engineering. She is an elected member of the National Academy of Engineering, the National Academy of Medicine, and the American Academy of Arts and Sciences.
Mykel D. Green is an Assistant Professor of Biomedical Engineering at Tulane University, where he leads the Regenerative Engineering and Equity Lab (REEL). His research focuses on developing biomaterial-based therapies informed by disease pathology to improve cell-based treatments. The lab s work centers on bone marrow transplantation for sickle cell disease and explores related therapeutic strategies for conditions such as postmenopausal health. By studying how factors like age, sex, and disease state influence hematopoietic stem cell function, Dr. Green s team designs materials and delivery systems that enhance transplantation outcomes and tissue recovery.
In addition to his research, Dr. Green is committed to advancing biomedical innovation and strengthening STEM education. His teaching integrates ethical and human
Quantitative engineering approaches to understand the multiscale biophysical biomechanical and rheological pathophysiology of sickle cell disease.- Decoding Sickle Cell Hemorheology with Supercomputing and AI.- In vitro approaches for the investigation of blood cell endothelial cell interactions in sickle cell disease.- Bioengineering Approaches to Understanding Sickle Cell Disease Large Artery Damage Hemodynamics and Inflammation.- Measuring Biophysical Properties of Single Red Blood Cells as Potential Biomarkers of Sickle Cell Disease.- Advancing Sickle Cell Disease Management Traditional Diagnostics to Comprehensive Red Blood Cell Health.- Development and proposed use of red cell function testing in SCD.- Gene editing based approaches for curing sickle cell disease.- Therapeutic Genome Engineering for the treatment of sickle cell disease.- Hemoglobin A Target for Sickle Cell Disease Drug Discove.
| Erscheint lt. Verlag | 11.2.2026 |
|---|---|
| Zusatzinfo | IV, 254 p. 52 illus., 44 illus. in color. |
| Verlagsort | Cham |
| Sprache | englisch |
| Maße | 155 x 235 mm |
| Themenwelt | Medizin / Pharmazie ► Physiotherapie / Ergotherapie ► Orthopädie |
| Technik | |
| Schlagworte | Biomarkers • CRISPR • gene therapy • Molecular therapeutics • sickle cell diagnostics • sickle cell disease • small molecules |
| ISBN-10 | 3-032-12531-6 / 3032125316 |
| ISBN-13 | 978-3-032-12531-6 / 9783032125316 |
| Zustand | Neuware |
| Informationen gemäß Produktsicherheitsverordnung (GPSR) | |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
